Tilray

Tilray Brands reported record fiscal 2026 revenue of about $915 million and an 11% rise in adjusted EBITDA to $61.1 million, with adjusted net income nearly doubling to $12.2 million. The results nonetheless missed sell-side forecasts and the company recorded a GAAP net loss of $49.6 million. Management guided to modest adjusted EBITDA growth for fiscal 2027 and has reduced debt largely through dilutive debt-for-equity swaps, while cannabis now represents only 29% of sales, leaving investors hesitant to drive the stock higher. » Más en finance.yahoo.com

Tilray has expanded its annual cultivation capacity from 210 to about 275 tonnes, mainly through production increases in Quebec and at the EU‑GMP‑certified plant in Portugal. Quebec now supplies large volumes to sites in Portugal and Australia, is aiming for EU‑GMP certification within 12 months and has built up inventories for international markets. In Germany the Aphria RX facility is running at full capacity and the new ARX brand has been launched, strengthening Tilray’s supply infrastructure for Europe, the UK and other regulated markets. » Más en finanzen.net

Tilray will cease beer production at its Terrapin brewery in Athens, Georgia and move brewing to other facilities in its US network from 25 September as part of efforts to optimise its brewing operations. The taproom, warehouse and repack operations in Athens will remain open and Terrapin will stay in Tilray’s craft beer portfolio. The change follows broader beverage restructuring under ‘Project 420’, which has included facility closures, brand adjustments and disposals aimed at improving profitability; Tilray reported beverage net revenue of $254m for the year to 31 May 2026, with gross profit of $91.2m. » Más en finance.yahoo.com